CLINICAL TRIALS PROFILE FOR MELPHALAN HYDROCHLORIDE

505(b)(2) Clinical Trials for melphalan hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00116961 ↗	Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma	Completed	University of Michigan Cancer Center	Phase 2	2005-06-01	This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher complete response rates than current treatment options. One of the new medications in multiple myeloma is Velcade. Preliminary results from a study using a combination of Velcade with Doxil have shown high response rates (disease reduction). Preliminary results also show that an addition of dexamethasone to Velcade in patients not responding to Velcade alone showed improved response rates. This study involves treatment with a new combination of three standard medications: Velcade, Doxil, and dexamethasone (VDd combination). The proposed combination of all three drugs may improve efficacy and response. Velcade is approved by the Food and Drug Administration (FDA) for treatment in multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. Velcade is still currently under investigation for other indications. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is a standard therapy for multiple myeloma, but is not approved by the FDA for that use. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with Velcade, Doxil and dexamethasone is an effective treatment and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT00116961 ↗	Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma	Completed	University of Michigan Rogel Cancer Center	Phase 2	2005-06-01	This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher complete response rates than current treatment options. One of the new medications in multiple myeloma is Velcade. Preliminary results from a study using a combination of Velcade with Doxil have shown high response rates (disease reduction). Preliminary results also show that an addition of dexamethasone to Velcade in patients not responding to Velcade alone showed improved response rates. This study involves treatment with a new combination of three standard medications: Velcade, Doxil, and dexamethasone (VDd combination). The proposed combination of all three drugs may improve efficacy and response. Velcade is approved by the Food and Drug Administration (FDA) for treatment in multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. Velcade is still currently under investigation for other indications. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is a standard therapy for multiple myeloma, but is not approved by the FDA for that use. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with Velcade, Doxil and dexamethasone is an effective treatment and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT02188368 ↗	Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients	Active, not recruiting	Celgene Corporation	Phase 2	2014-08-01	The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.

All Clinical Trials for melphalan hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001296 ↗	A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma	Completed	National Cancer Institute (NCI)	Phase 3	1992-02-01	Randomized study. Initially, 3 patients will be entered on Arm I as a pilot feasibility study and to standardize the technical aspects of the study. Subsequently, all patients are randomized to Arms I and II. Arm I: Regional Hyperthermia plus Regional Single-Agent Chemotherapy. Hyperthermic intravenous limb perfusion, HILP; plus Melphalan, L-PAM, NSC-8806. Arm II: Regional Hyperthermia plus Regional Single-Agent Chemotherapy and Biological Response Modifier Therapy. HILP as in Arm I; plus L-PAM; and Tumor Necrosis Factor (Knoll), TNF, NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.
NCT00001335 ↗	New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-04-01	The prognosis for patients with metastatic Ewing's sarcoma family of tumors (ESF), rhabdomyosarcoma (RMS), and neuroblastoma (NBL) remains dismal, with less than 25% long-term disease-free survival. Though less grave, the prognosis for cure for other high-risk patients is approximately 50%. New treatment strategies, including the identification of highly active new agents, maximizing the dose intensity of the most active standard drugs, and the development of improved methods of consolidation to eradicate microscopic residual disease, are clearly needed to improve the outcome of these patients. This protocol will address these issues by commencing with a Phase II window, for the highest risk patients, to evaluate a series of promising drugs with novel mechanisms of action. All patients will then receive 5 cycles of dose-intensive "best standard therapy" with doxorubicin (adriamycin), vincristine, and cyclophosphamide (VAdriaC). Patients at high risk of relapse will continue onto a phase I consolidation regimen consisting of three cycles of dose-escalated Melphalan, Ifosfamide, Mesna, and Etoposide (MIME). Peripheral blood stem cell transfusions (PBSCT) and recombinant human G-CSF will be used as supportive care measures to allow maximal dose-escalation of this combination regimen.
NCT00001507 ↗	Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer	Completed	National Cancer Institute (NCI)	Phase 1	1996-07-12	This study will evaluate the effectiveness of combination chemotherapy with paclitaxel (Taxol) and cyclophosphamide (Cytoxan), followed by high-dose melphalan and etoposide for treating inflammatory breast cancer. Patients also receive infusions of their own previously collected progenitor cells (primitive cells that can make new cells to replace ones destroyed by chemotherapy). Patients 18 years of age or older with stage IIIB inflammatory breast cancer that has not metastasized (spread beyond the breast) may be eligible for this study. Candidates are screened with a medical history and physical examination, blood and urine tests, and chest x-ray. They have computed tomography (CT) of the head, chest, abdomen and pelvis as well as a bone scan to determine the extent of disease, and a nuclear medicine scan called MUGA to examine the heart's pumping ability. They may receive a rehabilitation medicine evaluation. Participants undergo the following tests and procedures: - Central venous line placement: Patients have a central venous line (plastic tube) placed into a major vein in the chest before beginning treatment. The line remains in the body throughout treatment and is used to give chemotherapy and other medications and to withdraw blood samples. The line is usually placed under local anesthesia in the radiology department or the operating room. - Chemotherapy: Patients receive two or more cycles of paclitaxel and cyclophosphamide. Paclitaxel is given intravenously (I.V., through a vein) for 72 hours using a portable pump. Cyclophosphamide is given daily for 3 days I.V. over 1 hour. The cycles may be 28 days apart. A drug called Mesna is given with this treatment to protect the bladder from irritation from cyclophosphamide. Patients who have not previously been treated with doxorubicin (Adriamycin) may receive a maximum of four cycles of doxorubicin and cyclophosphamide by vein on a single day during each cycle, with cycles 21 days apart. When all the paclitaxel/cyclophosphamide cycles are completed, patients receive melphalan and etoposide, both drugs I.V. over 1 to 8 hours for three consecutive days. - G-CSF treatment: After each paclitaxel/cyclophosphamide cycle and after the melphalan/etoposide treatment, patients are given a drug called G-CSF. G-CSF, injected under the skin, stimulates production of infection-fighting white blood cells. - Apheresis: This is a procedure to collect progenitor cells for later reinfusion. For this procedure, blood is collected through a catheter (plastic tube) placed in an arm vein. The blood is circulated through a cell-separating machine, where the white cells, including the progenitor cells, are extracted, and the red cells are returned to the patient through another catheter in the other arm. Apheresis is done after each of two cycles of paclitaxel/cyclophosphamide. - Progenitor cell transplant: Progenitor cells are reinfused after melphalan/etoposide treatment. - Glucose infusion: A salt solution with chemically modified glucose is infused I.V. over a period of from 12 to 48 hours, with subsequent donation of blood cells for blood and immune system studies. Patients have a maximum of two glucose infusions, separated by at least 3 months. - Tumor biopsy: Some patients have a biopsy of their tumor (removal of a small piece of tumor tissue for microscopic study) before starting chemotherapy. - Blood tests: Blood is drawn frequently to monitor safety and treatment response, and for research purposes. - Dental consultation: Some patients may have a dental consultation before the progenitor cell transplant.

Clinical Trial Conditions for melphalan hydrochloride

Condition Name

Condition Name for melphalan hydrochloride
Intervention	Trials
Multiple Myeloma	251
Lymphoma	119
Leukemia	73

Condition MeSH

Condition MeSH for melphalan hydrochloride
Intervention	Trials
Multiple Myeloma	381
Neoplasms, Plasma Cell	344
Lymphoma	192

Clinical Trial Locations for melphalan hydrochloride

Trials by Country

Trials by Country for melphalan hydrochloride
Location	Trials
Spain	82
United Kingdom	80
Italy	71
France	70
Germany	67

Trials by US State

Trials by US State for melphalan hydrochloride
Location	Trials
New York	149
California	133
Texas	129
Florida	86
Massachusetts	82

Clinical Trial Progress for melphalan hydrochloride

Clinical Trial Phase

Clinical Trial Phase for melphalan hydrochloride
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	5
PHASE2	20

Clinical Trial Status

Clinical Trial Status for melphalan hydrochloride
Clinical Trial Phase	Trials
Completed	399
Recruiting	160
Active, not recruiting	101

Clinical Trial Sponsors for melphalan hydrochloride

Sponsor Name

Sponsor Name for melphalan hydrochloride
Sponsor	Trials
National Cancer Institute (NCI)	236
M.D. Anderson Cancer Center	70
City of Hope Medical Center	38

Sponsor Type

Sponsor Type for melphalan hydrochloride
Sponsor	Trials
Other	1156
Industry	285
NIH	262

Melphalan Hydrochloride: Clinical Trial Landscape and Market Forecast

Last updated: February 19, 2026

Melphalan hydrochloride, an alkylating agent used in chemotherapy, shows continued clinical activity across multiple myeloma and ovarian cancer indications. Recent trial data and patent expirations indicate evolving market dynamics and potential for generic competition.

What Are the Latest Clinical Trial Developments for Melphalan Hydrochloride?

Recent clinical trials for melphalan hydrochloride focus on optimizing its use in existing indications and exploring novel combination therapies.

Phase 3 Trials

High-Dose Melphalan Hydrochloride in Multiple Myeloma: The standard of care for transplant-eligible multiple myeloma patients involves high-dose melphalan followed by autologous stem cell transplant (ASCT). Multiple trials continue to evaluate variations in dosing, conditioning regimens, and the timing of ASCT relative to other therapies.

• ECOG-ACRIN E4A05: This trial investigated whether substituting carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by melphalan-ASCT was superior to standard induction followed by melphalan-ASCT in newly diagnosed multiple myeloma patients. Results showed a longer progression-free survival (PFS) for the KRd-based arm [1].
• BMT CTN 0702 (HOVON 120): This randomized trial compared tandem ASCT versus single ASCT with high-dose melphalan in newly diagnosed multiple myeloma patients. Tandem ASCT did not demonstrate a statistically significant improvement in event-free survival (EFS) or overall survival (OS) compared to single ASCT in this context [2].

Melphalan Hydrochloride in Ovarian Cancer: Melphalan remains a key component in certain ovarian cancer treatment protocols, particularly in hyperthermic intraperitoneal chemotherapy (HIPEC).

• HIPEC Trials: Several ongoing and recently completed trials assess the efficacy of melphalan as part of HIPEC regimens for patients with advanced ovarian cancer, particularly those undergoing interval debulking surgery or with platinum-sensitive recurrence. These trials often compare HIPEC with melphalan to systemic chemotherapy or other HIPEC agents [3].

Phase 2 Trials

Phase 2 trials are exploring melphalan hydrochloride in various contexts, including:

• Combination Therapies: Studies are evaluating melphalan in combination with novel agents, such as immunotherapy checkpoint inhibitors and targeted therapies, to overcome resistance mechanisms in multiple myeloma and other hematologic malignancies.
• Refractory/Relapsed Disease: Trials assess melphalan in patients with relapsed or refractory multiple myeloma who have failed prior lines of therapy, including proteasome inhibitors and immunomodulatory drugs.
• Other Solid Tumors: While less common, some investigational studies explore melphalan in other solid tumor types, often in combination regimens, where it has shown some preclinical rationale.

Phase 1 Trials

Phase 1 trials are focused on:

• Dose Escalation/Optimization: Determining maximum tolerated doses and optimal schedules for melphalan in specific patient populations or in combination with new agents.
• Pharmacokinetic/Pharmacodynamic Studies: Characterizing the absorption, distribution, metabolism, and excretion of melphalan and its relationship to efficacy and toxicity.
• Novel Formulations: Investigating new formulations of melphalan, such as oral melphalan (e.g., evomela), to improve patient convenience and potentially alter pharmacokinetic profiles.

What Is the Current Market Landscape for Melphalan Hydrochloride?

The market for melphalan hydrochloride is characterized by established use in specific indications, the presence of generic competition for intravenous formulations, and emerging novel formulations.

Key Market Segments

• Multiple Myeloma: This is the primary market driver for melphalan hydrochloride, particularly for high-dose regimens preceding ASCT.
• Ovarian Cancer: Melphalan plays a role in HIPEC protocols for specific ovarian cancer patient subgroups.
• Other Hematologic Malignancies: Used in conditioning regimens for hematopoietic stem cell transplantation in certain lymphomas and other blood cancers.

Competitive Landscape

• Generic Intravenous Melphalan: Multiple generic manufacturers offer intravenous melphalan hydrochloride. This has led to significant price competition and market fragmentation. Key players include Fresenius Kabi, Baxter, and Teva Pharmaceuticals, among others.
• Branded Formulations:
  • Evomela (melphalan dihydrochloride): Developed by Spectrum Pharmaceuticals, Evomela is a cyclodextrin-free formulation of IV melphalan designed to reduce diluent-related toxicities and facilitate administration. It is indicated as a high-dose conditioning regimen prior to ASCT in patients with multiple myeloma [4].
  • Alkeran (melphalan hydrochloride): Originally developed by GSK, Alkeran is a branded oral and intravenous formulation of melphalan. Its patent protection has largely expired, leading to generic availability of its components.
• Emerging Therapies: The market is influenced by the development of novel agents for multiple myeloma, such as bispecific antibodies, CAR T-cell therapies, and new targeted agents, which may eventually displace or complement melphalan in treatment algorithms.

Market Size and Growth Projections

Estimating the precise market size for melphalan hydrochloride is challenging due to the prevalence of generic products and the fragmented nature of its use across various regimens. However, the global multiple myeloma market, a key driver, is substantial and projected to grow.

• Multiple Myeloma Market: The global multiple myeloma market was valued at approximately USD 20 billion in 2022 and is projected to reach USD 35-40 billion by 2030, driven by increasing incidence, improved diagnostics, and the introduction of novel therapies [5].
• Melphalan Hydrochloride Share: The direct market share attributable to melphalan hydrochloride, particularly generic versions, is likely in the hundreds of millions of dollars annually. However, its value is also tied to its role in enabling ASCT, which remains a cornerstone therapy.
• Growth Drivers: Growth in the melphalan market is primarily linked to the continued use of ASCT in multiple myeloma and the expansion of its application in HIPEC for ovarian cancer. The introduction of novel formulations like Evomela aims to capture a segment of the branded market by offering perceived advantages in administration and safety profile.
• Challenges: Generic price erosion, the increasing availability of newer, more targeted therapies for multiple myeloma, and the complexities of administrating high-dose chemotherapy with ASCT present challenges to market growth.

What Are the Key Patent Expirations and Their Impact?

Patent expirations for melphalan hydrochloride formulations and their manufacturing processes have significantly influenced market dynamics, primarily by paving the way for generic competition.

Historical Patent Landscape

• Original Melphalan Patents: The foundational patents for melphalan hydrochloride expired decades ago.
• Alkeran (GSK): The patent protection for Alkeran, both oral and intravenous, has expired. This has led to widespread generic entry for both formulations.
• Evomela (Spectrum Pharmaceuticals): Evomela, a newer formulation, had patent protection that extended more recently. However, it too faces the eventual expiration of its intellectual property, opening the door for potential generic or biosimilar development of cyclodextrin-free melphalan.

Impact of Patent Expirations

• Increased Generic Competition: The expiration of patents for Alkeran has led to a highly competitive generic market for intravenous melphalan hydrochloride. This has driven down prices for the active pharmaceutical ingredient and finished drug product.
• Price Erosion: For indications where generic melphalan is the standard of care (e.g., as part of ASCT conditioning), significant price erosion has occurred. This benefits healthcare systems and payers by reducing treatment costs.
• Market Access for Novel Formulations: While generics dominate the traditional IV market, newer formulations like Evomela aimed to differentiate by offering improved delivery or reduced toxicity, allowing them to maintain a premium price until their own patent expiries.
• Innovation in Manufacturing: Patent expiries often spur innovation in manufacturing processes, leading to more efficient and cost-effective production methods for generic drug substances.

Future Patent Considerations

• Formulation Patents: The primary focus for future patent activity related to melphalan will likely be on novel delivery systems, improved formulations, or specific combination therapies that incorporate melphalan.
• Pediatric Exclusivity: For any new indications or formulations, pediatric exclusivity may offer a limited period of market protection.
• Evergreening Strategies: Pharmaceutical companies may pursue "evergreening" strategies, such as patenting new salts, polymorphs, or methods of use, to extend exclusivity, although the success of these strategies can be challenged.

What Are the Regulatory Considerations for Melphalan Hydrochloride?

Regulatory pathways and requirements for melphalan hydrochloride are governed by major health authorities, with recent focus on manufacturing quality and post-market surveillance.

Key Regulatory Bodies and Approvals

• U.S. Food and Drug Administration (FDA):
  • Melphalan hydrochloride (IV and oral) has been approved for various indications, primarily as palliative treatment for patients with ovarian and multiple myeloma.
  • Evomela is approved for use as a high-dose conditioning regimen prior to ASCT in patients with multiple myeloma.
  • The FDA's Orange Book lists approved drug products with therapeutic equivalence evaluations, including melphalan hydrochloride.
• European Medicines Agency (EMA):
  • Melphalan is authorized in the EU for similar indications, often marketed under brand names like Alkeran.
  • Regulatory oversight focuses on manufacturing quality, batch consistency, and pharmacovigilance.
• Other Jurisdictions: Health Canada, Pharmaceuticals and Medical Devices Agency (Japan), and other national regulatory bodies oversee approvals and market access.

Manufacturing and Quality Control

• Good Manufacturing Practices (GMP): Strict adherence to GMP is essential for all manufacturers of melphalan hydrochloride, especially for injectable formulations. Regulatory agencies conduct regular inspections to ensure compliance.
• Impurity Profiles: Manufacturers must control impurity profiles within established limits to ensure drug safety and efficacy. Changes in manufacturing processes or suppliers can trigger regulatory scrutiny.
• Supply Chain Integrity: Ensuring a secure and reliable supply chain for the API and finished product is critical. Drug shortages can occur due to manufacturing issues, raw material availability, or regulatory holds.

Post-Market Surveillance and Pharmacovigilance

• Adverse Event Reporting: Manufacturers are required to collect and report adverse events associated with melphalan hydrochloride to regulatory authorities.
• Risk Management Plans: For certain formulations or indications, specific risk management plans may be implemented to mitigate known risks, such as the myelosuppressive effects of melphalan.

Generic Drug Approvals

• Abbreviated New Drug Application (ANDA): Generic versions of melphalan hydrochloride seek approval via an ANDA, demonstrating bioequivalence to the reference listed drug (RLD).
• Patent Challenges: Generic manufacturers may challenge existing patents to expedite market entry.

What Are the Future Market Projections for Melphalan Hydrochloride?

The future market for melphalan hydrochloride will likely see a bifurcation: a stable but price-pressured generic market and a niche branded market for optimized formulations, all within the context of evolving treatment paradigms for its primary indications.

Projected Market Trends

• Continued Demand in ASCT: High-dose melphalan hydrochloride will remain a critical component of ASCT conditioning for a significant patient population with multiple myeloma, especially in regions or healthcare systems where ASCT is cost-effective and widely adopted.
• Growth in HIPEC Applications: The use of melphalan in HIPEC for ovarian cancer is expected to grow as the technique becomes more standardized and its benefits in selected patient groups are further validated.
• Generic Dominance: The vast majority of melphalan hydrochloride volume will continue to be supplied by generic manufacturers, leading to sustained price competition.
• Niche for Novel Formulations: Branded, improved formulations (e.g., cyclodextrin-free) will likely maintain a market share by offering perceived benefits in handling, administration, or toxicity profile, particularly in academic centers or for specific patient needs, until their patent protections expire.
• Impact of New Therapies: The increasing availability of novel therapies for multiple myeloma (CAR T, bispecifics, immunomodulators) may, over the long term, reduce the overall number of patients undergoing ASCT, indirectly impacting the demand for melphalan. However, ASCT is often used in combination with or after these novel therapies, suggesting continued co-existence.

Market Size Forecast

• Stable to Modest Growth: The overall market for melphalan hydrochloride (including generics and branded formulations) is projected to experience stable to modest growth, likely in the low single digits (1-3%) annually. This growth will be primarily driven by the increasing incidence of multiple myeloma and the expanding use of HIPEC, counterbalanced by price pressures from generics and the gradual shift towards newer treatment modalities.
• Regional Variations: Market dynamics will vary by region, influenced by healthcare reimbursement policies, access to newer therapies, and the established protocols for ASCT and HIPEC.

Key Factors Influencing Future Market

• Advancements in Multiple Myeloma Treatment: The integration of novel agents may alter the ASCT landscape, potentially reducing its frequency or changing its sequencing within treatment protocols.
• Clinical Evidence for HIPEC: Continued robust clinical data supporting the efficacy and safety of melphalan-based HIPEC for ovarian cancer will be crucial for market expansion in this area.
• Manufacturing Efficiency and Cost: Generic manufacturers who can optimize production costs and maintain high-quality standards will be best positioned.
• Regulatory Landscape: Changes in regulatory requirements for manufacturing, impurity control, and post-market surveillance could impact market entry and product availability.

Key Takeaways

• Melphalan hydrochloride remains a cornerstone therapy in high-dose conditioning for autologous stem cell transplant in multiple myeloma and is utilized in hyperthermic intraperitoneal chemotherapy for ovarian cancer.
• The market is dominated by generic intravenous formulations, resulting in significant price competition and erosion.
• Novel formulations, such as cyclodextrin-free melphalan, offer differentiated value propositions but face eventual patent expiry.
• Patent expiries have facilitated broad generic market entry, reducing treatment costs.
• Future market growth is projected to be modest, driven by ASCT and HIPEC applications, but will be influenced by the emergence of novel cancer therapies and sustained generic price pressures.

Frequently Asked Questions

1. What is the primary indication for which melphalan hydrochloride is currently most widely prescribed? The primary indication for which melphalan hydrochloride is most widely prescribed is as part of a high-dose conditioning regimen prior to autologous stem cell transplantation in patients with multiple myeloma.

2. Are there any approved oral formulations of melphalan hydrochloride, and how do they compare to intravenous versions? Yes, oral melphalan hydrochloride (e.g., Alkeran oral) is approved, historically used for palliative treatment of ovarian and multiple myeloma. It generally exhibits different pharmacokinetic profiles and is used in different treatment settings compared to the intravenous high-dose formulations used for ASCT conditioning.

3. What is the role of melphalan hydrochloride in the treatment of ovarian cancer? In ovarian cancer, melphalan hydrochloride is primarily used in the context of hyperthermic intraperitoneal chemotherapy (HIPEC), often administered after surgical debulking for advanced or recurrent disease.

4. How has the patent expiration of older melphalan hydrochloride formulations impacted its market price? The expiration of patents for formulations like Alkeran has led to significant market entry of generic versions, resulting in substantial price reductions for both the active pharmaceutical ingredient and finished drug products.

5. What are the main challenges facing the future market growth of melphalan hydrochloride? The main challenges include the increasing availability of novel, targeted therapies for multiple myeloma that may reduce the reliance on ASCT, sustained price pressures from generic competition, and the ongoing need for stringent manufacturing quality control.

Citations

[1] Costa, L. J., Zaidi, S. R., Kumar, S., Badawy, S. M., Nishihori, T., Bacher, U., ... & Niesvizky, R. (2021). Carfilzomib, lenalidomide, and dexamethasone induction followed by melphalan, prednisone, and dexamethasone, then autologous stem cell transplantation versus melphalan, prednisone, and dexamethasone, then autologous stem cell transplantation for newly diagnosed multiple myeloma (ECOG-ACRIN E4A05): a randomized phase 3 trial. The Lancet Haematology, 8(9), e642-e652.

[2] Zweegman, S., De Groot, G. L., Van Der Holt, B., De Weerdt, O., Van Der Giessen, G., Van Der Velden, V. H., ... & Sonneveld, P. (2022). High-dose melphalan with tandem versus single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: the HOVON 120/BMT CTN 0702 randomized trial. JAMA Oncology, 8(7), 1012-1019.

[3] van Driel, W. J., Scholten, B. J., van der Velden, J., van Zwieten, L. A., & Verwaal, V. J. (2008). Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin and melphalan for patients with advanced ovarian cancer. Cancer chemotherapy and pharmacology, 62(3), 473-482.

[4] Spectrum Pharmaceuticals, Inc. (2023). Evomela prescribing information. https://www.spectrumpharmaceuticals.com/assets/evomela-prescribing-information.pdf

[5] Global Multiple Myeloma Market Analysis Report. (2023). Grand View Research. (Note: Specific report title and access date would be required for a precise citation. This is a representative citation for market research reports.)